Correspondence 0001193125-24-084740 from Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc.
Date: April 2, 2024 · CIK: 0001855175 · Accession: 0001193125-24-084740
AI Filing Summary & Sentiment
File numbers found in text: 333-278003
Letter
VIA EDGAR Division of Corporation Finance Attention: CIK No: 0001855175 Request for Acceleration of Effective Date Requested Date: Thursday, April 4, 2024 Requested Time: 4:00 P.M. Eastern Time
Dear Ladies and Gentlemen:
Pursuant to Rule 460 under the Securities Act of 1933, as amended (the “Securities Act”), we, the representatives of the underwriters (the “Representatives”), wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the public offering of shares of the Registrant’s Class A common stock, as many copies of the preliminary prospectus of Contineum Therapeutics, Inc. (the “Registrant”) as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
We, the undersigned Representatives, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, in connection with the proposed offering.
In accordance with Rule 461 of the Securities Act, we hereby join in the request of the Registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time on April 4, 2024, or such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission. We, the undersigned Representatives, confirm that the underwriters are aware of their obligations under the Securities Act.
[Signature Page Follows]
Very truly yours,
GOLDMAN SACHS & CO. LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP April 2, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Daniel Crawford Laura Crotty Ibolya Ignat Kevin Juhar Re: Contineum Therapeutics, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed April 1, 2024 File No. 333-278003 CIK No: 0001855175 Request for Acceleration of Effective Date Requested Date: Thursday, April 4, 2024 Requested Time: 4:00 P.M. Eastern Time Dear Ladies and Gentlemen: Pursuant to Rule 460 under the Securities Act of 1933, as amended (the “Securities Act”), we, the representatives of the underwriters (the “Representatives”), wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the public offering of shares of the Registrant’s Class A common stock, as many copies of the preliminary prospectus of Contineum Therapeutics, Inc. (the “Registrant”) as appears to be reasonable to secure adequate distribution of the preliminary prospectus. We, the undersigned Representatives, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, in connection with the proposed offering. In accordance with Rule 461 of the Securities Act, we hereby join in the request of the Registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time on April 4, 2024, or such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission. We, the undersigned Representatives, confirm that the underwriters are aware of their obligations under the Securities Act. [Signature Page Follows] Very truly yours, GOLDMAN SACHS & CO. LLC MORGAN STANLEY & CO. LLC As representatives of the several underwriters listed in Schedule I to the Underwriting Agreement GOLDMAN SACHS & CO. LLC By: /s/ Lyla Bibi Maduri Name: Lyla Bibi Maduri Title: Managing Director MORGAN STANLEY & CO. LLC By: /s/ Chirag D. Surti Name: Chirag D. Surti Title: Executive Director cc: Carmine Stengone, Chief Executive Officer and President, Contineum Therapeutics, Inc. Jeffrey Thacker, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP Ryan J. Gunderson, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP Leanne A. Gould, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP Frank F. Rahmani, Sidley Austin LLP Samir A. Gandhi, Sidley Austin LLP J. Carlton Fleming, Sidley Austin LLP Kostian Ciko, Sidley Austin LLP [Signature Page to Underwriter Acceleration Request]